Prior art — US Patent 12419895

As a senior patent analyst on April 30, 2026, I have identified and analyzed the most relevant prior art for U.S. Patent 12,419,895 based on the citations likely to have been considered during its prosecution, including those mentioned within the patent's own background description.

The analysis below focuses on potential anticipation under 35 U.S.C. § 102. For a claim to be anticipated, a single prior art reference must disclose, either expressly or inherently, each and every element of the claim. The priority date of US 12,419,895 is November 14, 2014; therefore, any reference published or filed before this date is considered prior art.

Analysis of Prior Art References

The following references are evaluated for their potential to anticipate the independent claims (1, 8, 12, 16, and 17) of the '895 patent.

1. U.S. Patent No. 6,197,765 B1 ("'765 patent")

Full Citation: U.S. Patent 6,197,765 B1, "Methods for treating syndrome X," filed by inventor Al-Ali, assigned to Andro-Tech, LLC.
Dates: Filed: June 1, 1998; Issued: March 6, 2001. This patent predates the '895 patent's priority date.
Brief Description: The '765 patent discloses a method of treating Syndrome X (also known as metabolic syndrome) and its associated symptoms, which include central obesity, hyperinsulinemia, and impaired glucose tolerance. The method involves the administration of diazoxide, a known K-ATP channel opener. The patent focuses on correcting metabolic abnormalities related to insulin resistance and does not mention Prader-Willi Syndrome (PWS).
Anticipation Analysis (35 U.S.C. § 102):
- Claims 1, 8, 12, 16, 17: The '765 patent does not anticipate any of the independent claims of US 12,419,895.
- Reasoning: A critical element of all independent claims in the '895 patent is that the method is for treating a "subject having Prader-Willi Syndrome." The '765 patent makes no mention of PWS. While it teaches the administration of a K-ATP channel opener (diazoxide) for treating obesity, this disclosure is for a general population with Syndrome X. Failure to disclose the specific patient population (PWS subjects) is sufficient to defeat a finding of anticipation. Furthermore, the '765 patent does not explicitly disclose the specific claimed outcomes of increasing lean body mass (Claim 1), reducing hyperphagia (Claim 8), or the combination therapy with growth hormone (Claims 16 and 17).

2. U.S. Patent No. 5,284,845 ("'845 patent")

Full Citation: U.S. Patent 5,284,845, "Method of treating non-insulin dependent diabetes mellitus," filed by inventors Tipper et al., assigned to Atecs International, Inc.
Dates: Filed: February 18, 1993; Issued: February 8, 1994. This patent predates the '895 patent's priority date.
Brief Description: The '845 patent describes a method for normalizing blood glucose and insulin levels in individuals who exhibit elevated glucose and abnormal insulin levels during an oral glucose tolerance test. The method comprises administering a low dose of diazoxide before each meal. The disclosure is aimed at treating a pre-diabetic state.
Anticipation Analysis (35 U.S.C. § 102):
- Claims 1, 8, 12, 16, 17: The '845 patent does not anticipate any of the independent claims of US 12,419,895.
- Reasoning: Similar to the '765 patent, the '845 patent fails to disclose the specific patient population of "subject[s] having Prader-Willi Syndrome." Its teaching is directed at individuals with specific glucose and insulin abnormalities, not a genetic disorder like PWS. It also fails to teach the claimed endpoints of increasing lean body mass, reducing hyperphagia, or reducing body fat as the goal of the treatment.

3. Publication WO 98/10786 A1 ("WO '786")

Full Citation: WIPO Patent Application Publication WO/1998/010786, "Methods for Treating Syndrome-X and Associated Pathologies," filed by inventor Al Ali.
Dates: Priority Date: September 12, 1996; Publication Date: March 19, 1998. This publication predates the '895 patent's priority date.
Brief Description: This international patent application is the counterpart to the U.S. '765 patent and contains a similar disclosure. It describes using diazoxide to treat Syndrome X and its associated conditions, including obesity.
Anticipation Analysis (35 U.S.C. § 102):
- Claims 1, 8, 12, 16, 17: WO '786 does not anticipate any of the independent claims of US 12,419,895.
- Reasoning: The analysis is identical to that for the '765 patent. The reference fails to disclose the claimed method as being applied to subjects with Prader-Willi Syndrome and does not explicitly teach the claimed outcomes.

4. Salehi, A., et al. "Diazoxide-induced opening of K(ATP) channels in beta-cells is mediated by SUR1."

Full Citation: Salehi, A., et al. "Diazoxide-induced opening of K(ATP) channels in beta-cells is mediated by SUR1 and is required for the diazoxide-induced inhibition of insulin secretion." Diabetes, vol. 54, no. 2, Feb. 2005, pp. 453-62. (URL: https://diabetesjournals.org/diabetes/article/54/2/453/16474/Diazoxide-Induced-Opening-of-KATP-Channels-in-Cells)
Date: Published: February 2005. This article predates the '895 patent's priority date.
Brief Description: This scientific paper details the mechanism of action for diazoxide, confirming that it opens K-ATP channels to inhibit insulin secretion. It discusses its use in treating congenital hyperinsulinism. While it does not focus on PWS, PWS is a known cause of transient neonatal hyperinsulinism, making this reference highly relevant to the general field.
Anticipation Analysis (35 U.S.C. § 102):
- Claims 1, 8, 12, 16, 17: This paper does not anticipate any of the independent claims of US 12,419,895.
- Reasoning: The paper describes the fundamental mechanism of the drug class but does not describe a method of treatment for PWS subjects. It does not disclose administering a K-ATP channel opener to a PWS subject for the purpose of increasing lean body mass, reducing hyperphagia, or reducing body fat. The context of the paper is mechanistic and related to hyperinsulinism, not the specific constellation of symptoms and outcomes claimed in the '895 patent for the PWS population.

5. Carrel, A.L., et al. "Benefits of long-term growth hormone therapy in Prader-Willi syndrome: a 4-year study."

Full Citation: Carrel, A.L., et al. "Benefits of long-term growth hormone therapy in Prader-Willi syndrome: a 4-year study." The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 4, Apr. 2002, pp. 1581-5. (URL: https://academic.oup.com/jcem/article/87/4/1581/2846592)
Date: Published: April 2002. This article predates the '895 patent's priority date.
Brief Description: This study reports on the well-established benefits of growth hormone (GH) therapy in children with Prader-Willi Syndrome. The authors explicitly state that GH treatment "favorably altered body composition by increasing lean body mass and decreasing fat mass." It also notes improvements in physical strength and agility. This reference establishes the standard of care and known effects of GH in PWS.
Anticipation Analysis (35 U.S.C. § 102):
- Claims 1, 8, 12: This paper does not anticipate these claims because it fails to disclose the core element of administering a K-ATP channel opener. The method described relies solely on growth hormone.
- Claims 16, 17: This paper does not anticipate these claims.
  - Claim 16 requires co-administering a K-ATP channel opener to a PWS subject already being treated with GH. This paper does not mention K-ATP channel openers.
  - Claim 17 requires co-administering growth hormone to a PWS subject already being treated with a K-ATP channel opener. This paper does not mention K-ATP channel openers.
- Reasoning: Although this reference discloses treating PWS subjects with a therapy (GH) that achieves an increase in lean body mass, it does not teach the specific combination therapy recited in claims 16 and 17, nor the K-ATP opener monotherapy of claims 1, 8, and 12. Therefore, it cannot anticipate any of the independent claims.